The parametric g-formula and inverse probability weighting

Slides:



Advertisements
Similar presentations
Allison Dunning, M.S. Research Biostatistician
Advertisements

Agency for Healthcare Research and Quality (AHRQ)
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
If we use a logistic model, we do not have the problem of suggesting risks greater than 1 or less than 0 for some values of X: E[1{outcome = 1} ] = exp(a+bX)/
A workshop introducing doubly robust estimation of treatment effects
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Informative Censoring Addressing Bias in Effect Estimates Due to Study Drop-out Mark van der Laan and Maya Petersen Division of Biostatistics, University.
To change this title, go to Notes Master
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Dynamic Treatment Regimes, STAR*D & Voting D. Lizotte, E. Laber & S. Murphy ENAR March 2009.
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Body Mass Index, Weight Change and Death in an Older Hypertensive Population: The SHEP Study Grant W Somes Stephen B Kritchevsky Marco Pahor Ronald I Shorr.
Survival Analysis: From Square One to Square Two
HSTAT1101: 27. oktober 2004 Odd Aalen
1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
MTPPI EPO Outcomes Research Presented to FDA /CDER Joint Meeting of the Cardiovascular and Renal Drugs & Drug Safety and Risk Management Advisory Committees.
FRAMING RESEARCH QUESTIONS The PICO Strategy. PICO P: Population of interest I: Intervention C: Control O: Outcome.
Lecture 8: Generalized Linear Models for Longitudinal Data.
October 15H.S.1 Causal inference Hein Stigum Presentation, data and programs at:
The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.
Assessing ETA Violations, and Selecting Attainable/Realistic Parameters Causal Effect/Variable Importance Estimation and the Experimental Treatment Assumption.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Article Review Cara Carty 09-Mar-06. “Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Estimating the Effects of Two Classes of Drugs on Hemoglobin with a Doubly Robust Method APHA conference, October 30, 2012 Brian P. Johnson, MPH, Charles.
1 1 Using Marginal Structural Model to Estimate and Adjust for Causal Effect of Post- discontinuation Chemotherapy on Survival in Cancer Trials Y. Wang,
Epidemiologic design from a sampling perspective Epidemiology II Lecture April 14, 2005 David Jacobs.
Dependencies Complex Data in Meta-analysis. Common Dependencies Independent subgroups within a study (nested in lab?) Multiple outcomes on the same people.
Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.
Empirical Efficiency Maximization: Locally Efficient Covariate Adjustment in Randomized Experiments Daniel B. Rubin Joint work with Mark J. van der Laan.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.
Biostatistics Case Studies 2006 Peter D. Christenson Biostatistician Session 4: An Alternative to Last-Observation-Carried-Forward:
Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
2007May221 Journal Club for Analysis of Complex Datasets Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic,
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Marginal structural models: application Daniel SPER Anaheim June
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Summary: connecting the question to the analysis(es) Jay S. Kaufman, PhD McGill University, Montreal QC 26 February :40 PM – 4:20 PM National Academy.
Introduction to Causal Inference Methods Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS.
Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
Meta-analysis of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Constructing Inverse Probability Weights for Dynamic Interventions
Putting it all together CIMPOD 2017, February 27-28
Survival-time inverse-probability- weighted regression adjustment
Constructing Inverse Probability Weights for Dynamic Interventions
Threats to validity in observational studies
Accounting for uncertainty in the timing of seroconversion in combined models for pre- and post-treatment CD4 counts in HIV-patients Oliver Stirrup, Andrew.
Harvard T.H. Chan School of Public Health
Presenter: Wen-Ching Lan Date: 2018/03/28
Narrative Reviews Limitations: Subjectivity inherent:
Miguel Hernán departments of epidemiology and biostatistics
Counterfactual models Time dependent confounding
Presentation transcript:

The parametric g-formula and inverse probability weighting Sara Lodi Harvard T.H. Chan School of Public Health slodi@hsph.harvard.edu February 26th 2016

Recap from yesterday Observational studies should emulate a target trial without baseline randomization G-methods are needed in the presence of treatment confounder feedback IPW is used to correct for time-varying confounding and informative censoring

Treatment confounder feedback At: Antiretroviral therapy Y: Death Lt: CD4 cell count U: Immunologic status A0 L1 A1 Y U The time-varying confounders are affected by previous treatment

IPW Inverse probability weighting of marginal structural models Pseudo-population with no confounding by L1 Any outcome model can be used (marginal structural model)

Inverse probability weighting of marginal structural models A model for treatment Covariates: time-varying confounders A model for outcome with weights Covariates: time-varying treatment and (optional) baseline confounders (no time-varying confounders)

Today.. Introduce the g-formula Another method to adjust for treatment confounder feedback… Discuss differences and similarities between the g-formula and IPW

Example: when to start antiretroviral treatment (ART) in HIV-positive patients Combined antiretroviral treatment (ART) is effective in reducing the risk of AIDS and mortality HIV is now considered a chronic disease Life-long treatment Debate on optimal time to initiate ART

Early initiation 500 or AIDS 350 or AIDS Lodi et al. CID 2011

When to start ART TARGET TRIAL Eligibility criteria (HIV-CAUSAL Collaboration. Lancet HIV 2015) TARGET TRIAL Eligibility criteria HIV-1-infected, ART-naïve, CD4 count>500 Treatment strategies Immediate ART initiation Initiation at CD4 cell count of 500 or AIDS Initiation at CD4 cell count of 350 or AIDS Outcome Death Start/End follow-up From randomization to death, loss f-u, 7 years Analysis plan Risk of death at 7 years under each treatment strategy

Dynamic treatment strategy

In the observational data… Administrative censoring 1 June 2015 HIV diagnosis CD4 400 HIV-RNA 1000 ART started Treatment change Last visit HIV diagnosis CD4 200 HIV-RNA 10000 TB diagnosis Death HIV diagnosis CD4 600 HIV-RNA 1000 ART started Last visit L

In the observational data… No baseline randomization ART is a time-varying treatment ART initiation depends on prognostic factors that vary over time (time-varying confounders) such as CD4 count and HIV-RNA viral load

Treatment-confounder feedback At: Antiretroviral therapy Y: Death Lt: CD4 cell count U: Immunologic status A0 L1 A1 Y U The time-varying confounders are affected by previous treatment

Could use inverse probability weighting…

… or the g-formula First proposed in 1986 by Robins First realistic application to a complex longitudinal study published in 2009 (Taubman et al. AJE 2009) SAS software + documentation developed and publicly available online www.hsph.harvard.edu/causal/software.htm

G-formula Standardized risk Allows estimation and comparison of risks under hypothetical interventions in the presence of treatment confound feedback Simulates outcomes and time-varying confounders if all subjects in the study, contrary to the fact, had followed the intervention Can be viewed as an imputation method

G-formula as standardized risk Time-fixed confounding Standardised risk for fixed exposure 𝑎 ∗ and time-fixed confounder L a* = antiretroviral treatment (ART=1) Y = death L= CD4 count stratum (<350 or >=350 cells/mm3

G-formula as standardized risk Time-fixed confounding Standardised risk for fixed exposure 𝑎 ∗ and time-fixed confounder L Time-varying confounding Standardised risk for treatment strategy g* and time-varying confounder L g-formula a* = antiretroviral treatment (ART=1) Y = death L= CD4 count stratum (<350 or >=350 cells/mm3

G-formula Notation: k=0,1,…,𝐾 time after randomization 𝑔 treatment strategy (example: initiation at 2nd CD4<350) 𝑌 𝑘+1 outcome at time k+1 (composite event: NAIDS, AIDS or death) 𝐴 𝑘 treatment history up to time k (example: 0,0,0,…,1,1) 𝐿 𝑘 history of time-varying confounders (CD4 and HIV-RNA) up to time k

Parametric g-formula STEP 1. Regression models on the observed data to estimate each factor in the sum

Parametric g-formula STEP 1 A model for each time-varying confounder and for the outcome Covariates: baseline and time-varying confounders, treatment When to start ART example: Linear model for CD4 count Linear model for HIV-RNA Logistic model for death Time-varying confounders Outcome

Parametric g-formula STEP 2. Monte Carlo simulations For each treatment strategy, we use the model parameters to simulate a dataset in which all subjects follow the treatment strategy Simulate time-varying covariates and outcome at each time point (0,1,2,…) Simulations carried forward in time

Parametric g-formula STEP 2 When to start ART example: Simulate a dataset where all individuals start ART immediately Simulate a dataset where all individuals start ART at CD4 count<500 or AIDS Simulate a dataset where all individuals start ART at CD4 count<350 or AIDS

Parametric g-formula STEP 3 Use the simulated datasets to compute and compare the risk of the outcome under different treatment strategies Use bootstrap to compute confidence intervals HIV-CAUSAL Collaboration. Lancet HIV 2015

Parametric g-formula Assumptions No unmeasured or residual baseline or time-varying confounding Models for time-varying confounders and outcome should be correctly specified Positivity – the probability of having every value of the treatment is greater than zero Limitation G-null paradox

Other applications of the g-formula Estimation of the risk of coronary heart disease under interventions on risk factors (smoking, exercise, diet and weight loss) Taubman et al 2009 Estimation of the risk of adult onset asthma under interventions on BMI and physical activity Garcia-Aymerich J et al 2014

Inverse probability weighting G-formula Inverse probability weighting OR

Inverse probability weighting G-formula vs IPW (similarities) G-formula Inverse probability weighting Adjustment for time-varying confounders affected by prior exposure Same Compare multiple strategies simultaneously Assumptions: no unmeasured confounding, correct model specification and positivity

Inverse probability weighting G-formula vs IPW (differences) G-formula Inverse probability weighting Models for each time-varying covariates and outcome A model for treatment and a model the outcome Sensitive to model misspecification (errors reverberate in the simulations) Sensitive to extreme observations (large weights) Fully parametric approach based on max likelihood estimation (more efficient) Semi parametric approach (less efficient)

Summary G-formula estimates the counterfactual risk under hypothetical interventions Both the g-formula and IPW can be used to estimate the effect of interventions in the presence of treatment confounding feedback G-formula requires many models but in general gives more precise estimates (smaller confidence intervals)

References IPW and dynamic treatment strategies HIV-CAUSAL Coll. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons. Ann Intern Med. 2011 Apr 19;154(8):509-15 Applications of the g-formula HIV-CAUSAL Coll. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals. Lancet HIV. 2015 Aug;2(8):e335-43. Taubam et al. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol. 2009 Dec; 38(6): 1599–1611. Garcia-Aymerich et al. Incidence of adult-onset asthma after hypothetical interventions on body mass index and physical activity. Am J Epidemiol. 2014 Jan 1;179(1):20-6 G-formula macro www.hsph.harvard.edu/causal/software.htm